钠-葡萄糖协同转运蛋白-2抑制剂对心力衰竭相关功能性二尖瓣反流的疗效:随机对照试验的系统评价与荟萃分析。
完整摘要 · 中文译文
背景:功能性二尖瓣反流(FMR)常使心力衰竭(HF)复杂化,并预示不良预后。尽管钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)可改善心力衰竭患者的临床结局并诱导心脏逆向重构,但其对与心力衰竭严重程度相关的FMR的具体作用仍不确定。 方法:检索了5个数据库自建库至2026年7月21日的随机对照试验(RCT),这些试验评估了SGLT2i在已接受指南指导的药物治疗(GDMT)背景下用于成年心力衰竭合并慢性FMR患者的情况。主要结局为有效反流口面积(EROA)和反流体积(RV)较基线的变化。次要临床结局包括心力衰竭住院和心血管(CVS)死亡。采用随机效应模型。使用Cochrane RoB 2工具评估偏倚风险,并使用GRADE评估证据确定性。 结果:共纳入3项RCT,涉及455例患者。SGLT2i治疗与EROA(MD -0.086 cm2,95% CI -0.150至-0.022)和RV(MD -10.87 mL,95% CI -17.32至-4.43)的统计学显著降低相关,但观察到显著异质性(分别为I2 = 72.5%和I2 = 63.5%)。在留一法敏感性分析中,剔除EFFORT试验后,两项主要瓣膜结局的统计学显著性均丧失。证据确定性被评为低。 结论:在汇总分析中,在GDMT基础上加用SGLT2i与FMR严重程度降低相关;然而,这些发现在敏感性分析中并不稳健,并受限于低证据确定性。 的证据。临床事件的表观减少由于事件稀疏而需要谨慎解读。这些结果应被视为产生假设而非确证性,需要在大型前瞻性试验中进一步验证。 系统综述注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD420261462002,PROSPERO CRD420261385207。
完整摘要 · 英文原文
BACKGROUND: Functional mitral regurgitation (FMR) commonly complicates heart failure (HF) and portends a poor prognosis. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve clinical outcomes and induce cardiac reverse remodeling in HF, their specific effect on FMR associated with HF severity remains uncertain. METHODS: Five databases were searched from inception to 21 July 2026 for randomized controlled trials (RCTs) evaluating SGLT2i in adult patients with HF and chronic FMR on background guideline-directed medical therapy (GDMT). Primary outcomes were changes from baseline in effective regurgitant orifice area (EROA) and regurgitant volume (RV). Secondary clinical outcomes included HF hospitalization and cardiovascular (CVS) death. Random-effects models were used. Risk of bias was evaluated using the Cochrane RoB 2 tool, and certainty of evidence was assessed using GRADE. RESULTS: Three RCTs involving 455patients were included. SGLT2i therapy was associated with a statistically significant reduction in EROA (MD -0.086 cm2, 95% CI -0.150 to -0.022) and RV (MD -10.87 mL, 95% CI -17.32 to -4.43), but substantial heterogeneity was observed (I2 = 72.5% and I2 = 63.5%, respectively). On leave-one-out sensitivity analyses, statistical significance for both primary valvular outcomes was lost after omitting the EFFORT trial. The certainty of evidence was rated as low. CONCLUSION: Addition of SGLT2i to GDMT was associated with reductions in FMR severity in pooled analyses; however, these findings were not robust in sensitivity analyses and are limited by low certainty of evidence. The apparent reduction in clinical events requires cautious interpretation due to event sparsity. These results should be considered hypothesis-generating rather than confirmatory, warranting further validation in large-scale, prospective trials. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261462002, PROSPERO CRD420261385207.